ADC Therapeutics SA Weighted Average Exercise Price Of Share Options Forfeited In Share-based Payment Arrangement2019
ADC Therapeutics SA (ADCT) reported Weighted Average Exercise Price Of Share Options Forfeited In Share-based Payment Arrangement2019 of $13.29 per share for the 9-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Notes › Compensation Related Costs
ifrs-full:WeightedAverageExercisePriceOfShareOptionsForfeitedInSharebasedPaymentArrangement2019 · last filed 2023-11-07
- ADC Therapeutics SA weighted average exercise price of share options forfeited in share-based payment arrangement2019 for the quarter ending 2023-03-31 was $19.59, a 30.85% decline year-over-year.
- ADC Therapeutics SA weighted average exercise price of share options forfeited in share-based payment arrangement2019 for the quarter ending 2022-03-31 was $28.33, a 30.37% increase year-over-year.
- ADC Therapeutics SA weighted average exercise price of share options forfeited in share-based payment arrangement2019 for the quarter ending 2021-03-31 was $21.73.
| Period end | Weighted Average Exercise Price Of Share Options Forfeited In Share-based Payment Arrangement2019 3 month | Weighted Average Exercise Price Of Share Options Forfeited In Share-based Payment Arrangement2019 6 month | Weighted Average Exercise Price Of Share Options Forfeited In Share-based Payment Arrangement2019 9 month | Weighted Average Exercise Price Of Share Options Forfeited In Share-based Payment Arrangement2019 12 month |
|---|---|---|---|---|
| 2023-09-30 | $13.29 6-K · filed 2023-11-07 | |||
| 2023-06-30 | $16.14 6-K · filed 2023-08-08 | |||
| 2023-03-31 | $19.59 6-K · filed 2023-05-09 | |||
| 2022-12-31 | $23.27 20-F · filed 2023-03-15 | |||
| 2022-09-30 | $26.71 6-K · filed 2022-11-08 | |||
| 2022-06-30 | $27.12 6-K · filed 2022-08-09 | |||
| 2022-03-31 | $28.33 6-K · filed 2022-05-09 | |||
| 2021-12-31 | $24.82 20-F · filed 2023-03-15 | |||
| 2021-09-30 | $24.77 6-K · filed 2021-11-02 | |||
| 2021-06-30 | $25.22 6-K · filed 2021-08-03 | |||
| 2021-03-31 | $21.73 6-K · filed 2021-05-06 | |||
| 2020-12-31 | $19.83 20-F · filed 2023-03-15 | |||
| 2019-12-31 | $0.00 20-F · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |